Bioceltix S.A. (WSE:BCX)

Poland flag Poland · Delayed Price · Currency is PLN
94.00
-2.00 (-2.08%)
Sep 5, 2025, 5:02 PM CET
-2.08%
Market Cap462.90M
Revenue (ttm)n/a
Net Income (ttm)-14.49M
Shares Out4.92M
EPS (ttm)-3.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,867
Average Volume4,527
Open95.00
Previous Close96.00
Day's Range93.80 - 95.00
52-Week Range66.00 - 129.00
Beta1.37
RSI33.93
Earnings DateSep 18, 2025

About Bioceltix

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol BCX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.